A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors is a PHASE1 clinical asset sponsored by Eikon Therapeutics in Advanced Solid Tumors. SEO and diligence focus: EIK1004-001 (IMP1707-001), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.